Clinical Trials - AKBA

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06901505To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisRECRUITINGPHASE32025-07-242026-062026-06
NCT05082571Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseWITHDRAWNPHASE32025-012026-102026-07
NCT05082584Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsWITHDRAWNPHASE32025-012026-102026-07
NCT04707768Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsCOMPLETEDPHASE32021-06-182023-01-302023-01-06
NCT04299633Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of VadadustatCOMPLETEDPHASE12020-06-152020-09-282020-08-02
NCT04313153Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)COMPLETEDPHASE32020-05-272022-06-222021-11-26
NCT03992066Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney DiseaseCOMPLETEDPHASE12019-05-282020-07-152020-05-05
NCT03799627Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaCOMPLETEDPHASE22019-01-312020-07-152020-06-05
NCT03789032Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of VadadustatCOMPLETEDPHASE12018-10-032018-11-192018-11-09
NCT03657290A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG TabletCOMPLETEDPHASE12018-08-032018-10-162018-10-16
NCT03801759Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and FurosemideCOMPLETEDPHASE12018-07-202018-09-302018-09-30
NCT03801746Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and RifampinCOMPLETEDPHASE12018-07-202018-08-152018-08-15
NCT03801733Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and SimvastatinCOMPLETEDPHASE12018-06-172018-11-242018-11-24
NCT03799848A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic FunctionCOMPLETEDPHASE12018-06-122018-10-182018-10-18
NCT03639155A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy AdultsCOMPLETEDPHASE12018-04-122018-05-232018-05-23
NCT03254485A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)COMPLETEDPHASE22017-11-072019-08-192019-08-19
NCT03217591A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by AlbuminuriaCOMPLETEDPHASE22017-08-012019-08-202019-08-20
NCT03242967Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)WITHDRAWNPHASE32017-082018-02-122018-02-12
NCT03140722Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating AgentsTERMINATEDPHASE22017-05-022018-03-212018-03-21
NCT03054350Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)COMPLETEDPHASE22016-122018-01-242017-10-24
NCT03054337Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)COMPLETEDPHASE22016-102017-08-282017-07-04
NCT02892149Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)COMPLETEDPHASE32016-082020-03-302020-01-16
NCT02865850Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)COMPLETEDPHASE32016-072020-03-302020-01-31
NCT02680574Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)COMPLETEDPHASE32016-022020-07-312020-06-18
NCT02648347Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney DiseaseCOMPLETEDPHASE32015-122020-07-312020-06-04
NCT02502500Effect of AKB-6548 on the Pharmacokinetics of CelecoxibCOMPLETEDPHASE12015-072015-092015-07
NCT02412449Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult SubjectsCOMPLETEDPHASE12015-042015-042015-04
NCT02327546Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548COMPLETEDPHASE12014-122015-022014-12
NCT0226019316-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic HemodialysisCOMPLETEDPHASE22014-09-102015-07-222015-07-22
NCT02062203Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy VolunteersCOMPLETEDPHASE12014-012014-042014-04
NCT0190648920-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCOMPLETEDPHASE22013-07-232014-09-032014-09-03
NCT0138109442-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCOMPLETEDPHASE22011-06-152012-02-162012-02-16
NCT01235936Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCOMPLETEDPHASE22010-10-212011-052011-04-13
NCT04707573Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4COMPLETEDPHASE22010-07-082010-09-242010-09-24